MedGenome has announced the appointment of Dr Amit Kakar, from Novo Holdings, to its Board of Directors. This announcement comes on the heels of MedGenome's $50 million funding round led by Novo Holdings in August 2022. They have also appointed Navjeewan Khosla, Principal, Novo Holdings as Board Observer.

Dr Kakar is Senior Partner, Head of Novo Holdings Asia, and a healthcare professional with over 30 years of experience across key verticals including medical technology, R&D, manufacturing, pharma retail, drug discovery, clinical research, biotech, hospitals and diagnostic centres, primary and specialty care centres, among others.

His diverse experience also encompasses investing, operational and management roles across health-tech companies. He is currently part of the Board of Directors of Singapore-based life science company, ESCO, telemedicine portal – Doctor Anywhere and leading health tech firm Qure.ai. As a Senior Partner, Dr Kakar's expertise will help accelerate MedGenome's expansion plans.

Previously, Dr Kakar served as Head of M&A and Business Development at Everlife Asia in Singapore, was Head of Healthcare Investments at Avenue Capital Group and served in several senior leadership roles at GE Healthcare